CTIS.eu › Cities › France › Caen Cedex 9
Caen Cedex 9
France
295 total trials
135 recruiting
2025-520976-25-00
4
Relapsed/refractory multiple myeloma
2025-521039-35-00
5
Impact on delirium of the use of DEXmedetomidine as first-line sedati
2025-522060-32-00
4
STEMI (ST elevated Myocardial Infarction)
2025-522193-37-00
5
Septic arthritis
2025-522790-10-00
4
Non Small Cell Lung Cancer
2025-523481-24-00
5
Participants with Progressive Supranuclear Palsy Richardson Syndrome (
2024-516468-27-00
5
2026-04-07
Aneurysmal Subarachnoid Hemorrhage
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
2025-521775-31-00
5
2025-11-12
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
2024-518973-32-00
5
2025-07-03
Chronic Graft-Versus-Host Disease
2023-507936-20-00
5
2025-05-05
Acute myeloid leukemia
2024-512733-32-00
5
2025-03-31
Acute Myeloid Leukemia (AML)
2023-507633-21-01
5
2024-12-09
Multiple Sclerosis
2024-514799-42-00
4
2024-11-05
IDIOPATHIC PULMONARY FIBROSIS
2024-517004-11-00
5
2024-10-22
Chronic pulmonary aspergillosis
2024-511404-17-00
5
2024-10-07
Unresectable or metastatic NRAS mutant cutaneous melanoma
2024-516433-13-00
5
2024-09-19
Progressive multiple sclerosis
2023-509618-12-00
5
2024-09-11
Crohn's Disease (CD)
2024-515456-20-00
4
2024-08-13
Hepato carcinoma cancer
2023-508153-12-00
5
2024-03-26
Hospital-acquired pneumonia
2023-505486-92-00
4
2024-02-09
Small bowel adenocarcinoma
2022-500273-14-00
10
2023-07-17
Atherosclerotic cardiovascular disease in patients with ESKD
2022-500275-31-00
5
2023-06-20
Haemophilia A
2022-501709-11-00
5
2023-06-06
Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
Showing 25–48 of 295 trials